BRITISH MEDICAL BULLETIN

VOLUME THIRTY-NINE
1983

Number 1. OPIOID PEPTIDES

Scientific Editor . . . . . J HUGHES

★

Number 2. CHLAMYDIAL DISEASE

Scientific Editor . . . . . S DAROUGAR

★

Number 3. PROSTACYCLIN, THROMBOXANE AND LEUKOTRIENES

Scientific Editor . . . . . S MONCADA

★

Number 4. EARLY PRENATAL DIAGNOSIS

Scientific Editor . . . . . M A FERGUSON-SMITH

★

ISSN:0007-1420

CHURCHILL LIVINGSTONE · 5 BENTINCK STREET · LONDON · W1M 5RN

CONTENTS OF NUMBER 1

		PAGE
Introduction	*John Hughes & H W Kosterlitz*	1
Chemistry of opioid peptides	*J S Morley*	5
Central distribution of opioid peptides	*A Claudio Cuello*	11
Biogenesis, release and inactivation of enkephalins and dynorphins	*John Hughes*	17
β-Endorphin and related peptides in pituitary, brain, pancreas and antrum	*D G Smyth*	25
Classification of opioid receptors	*S J Paterson, L E Robson & H W Kosterlitz*	31
Molecular properties of opioid receptors	*Eric A Barnard & Catherine Demoliou-Mason*	37
Distribution and physiological significance of opioid receptors in the brain	*Samir F Atweh & Michael J Kuhar*	47
Opiates, second messengers and cell response	*Robert E West & Richard J Miller*	53
Electrophysiological analysis of opioid action in the central nervous system	*Graeme Henderson*	59
Electrophysiology of opioid peptides and sensory systems	*A W Duggan*	65
Actions and distributions of opioid peptides in peripheral tissues	*R Alan North & Terry M Egan*	71
Opioid peptide interactions with respiratory and circulatory systems	*D S McQueen*	77
The neuroendocrinology of opioid peptides	*Ashley Grossman & Lesley H Rees*	83
Behavioural effects of opioid peptides	*George F Koob & Floyd E Bloom*	89
Clinical perspectives in opioid peptides	*Vicky Clement-Jones & G M Besser*	95

Notes on Contributors 101

CONTENTS OF NUMBER 2

		PAGE
Introduction	*Barrie R Jones*	107
Chlamydial classification, development and structure	*M E Ward*	109
Trachoma	*S Darougar & Barrie R Jones*	117
Adult chlamydial ophthalmia (paratrachoma)	*N D Viswalingam, M S Wishart & R M Woodland*	123
Chlamydial infections in neonates and older children	*D Hobson, E Rees & N D Viswalingam*	128
Genital infection in men	*J D Oriel & G L Ridgway*	133
Chlamydial infection of the lower genital tract of women	*M J Hare & R N Thin*	138
Chlamydial salpingitis	*L Weström & P-A Mårdh*	145
Lymphogranuloma venereum	*J Schachter & A O Osoba*	151
Chlamydial infection in proctitis and Crohn's disease	*Patricia E Munday & David Taylor-Robinson*	155
Perihepatitis	*J P Bolton & S Darougar*	159
Psittacosis	*J T Macfarlane & A D Macrae*	163
Chlamydial infection in the aetiology of arthritis	*Andrew Keat, Brenda J Thomas & David Taylor-Robinson*	168
Animal models of chlamydial infection	*R M Woodland, A P Johnson & Maureen Tuffrey*	175
Detection of chlamydiae by isolation and direct examination	*R T Evans & R M Woodland*	181
Immune responses and chlamydial infections	*Marjorie A Monnickendam & J H Pearce*	187
Chlamydial serology	*J D Treharne, T Forsey & Brenda J Thomas*	194
Observations on and future trends in chlamydial research	*Barrie R Jones & David Taylor-Robinson*	201

Notes on Contributors 204

CONTENTS OF NUMBER 3

		PAGE
Abbreviations		
Introduction	*S Moncada & J R Vane*	209
Background to essential fatty acids and their prostanoid derivatives	*M A Crawford*	210
Synthesis and catabolism of cyclo-oxygenase products	*Y S Bakhle*	214
Lipoxygenase pathways	*Graham W Taylor & Howard R Morris*	219
Measurement of eicosanoids by gas chromatography and mass spectrometry	*Ian A Blair*	223
Measurement of eicosanoids by bioassay and radioimmunoassay	*John A Salmon*	227
Pharmacological interactions between prostacyclin and thromboxanes	*B J R Whittle & S Moncada*	232
Interactions between prostaglandins, leukotrienes and other mediators of inflammation	*T J Williams*	239
Immunoregulatory activity of arachidonic acid metabolites and their role in inflammation	*G P Lewis*	243
The pharmacology and pathophysiology of leukotriene B_4	*Michael A Bray*	249
Pharmacology of leukotrienes	*Priscilla J Piper*	255
Inhibition of phospholipase	*Geoffrey J Blackwell & Roderick J Flower*	260
Inhibition of cyclo-oxygenase and lipoxygenase	*G A Higgs & J R Vane*	265
The prostacyclin–thromboxane A_2 balance: pathophysiological and therapeutic implications	*S Bunting, S Moncada & J R Vane*	271
Lipid peroxidation in relation to prostacyclin and thromboxane physiology and pathophysiology	*Michael A Warso & William E M Lands*	277
Clinical pharmacology and potential of prostacyclin	*P J Lewis & C T Dollery*	281
Prostacyclin and extracorporeal circulation	*M J Weston*	285
Clinical aspects of the arachidonic acid–thromboxane pathway	*J R A Mitchell*	289

Notes on Contributors 296

CONTENTS OF NUMBER 4

		PAGE
Introduction	*M A Ferguson-Smith*	301
Genetic counselling and prenatal diagnosis	*P S Harper*	302
Ethical and legal aspects of early prenatal diagnosis	*M d'A Crawfurd*	310
Second-trimester amniocentesis and termination of pregnancy	*A C Turnbull & I Z MacKenzie*	315
Ultrasound visualization of congenital malformations	*S Campbell & J M Pearce*	322
Fetoscopy and fetal tissue sampling	*C H Rodeck & K H Nicolaides*	332
First-trimester chorion biopsy	*C H Rodeck & J M Morsman*	338
Application of recombinant DNA technology to prenatal detection of inherited defects	*S E Humphries & R Williamson*	343
Amniotic fluid cell types and culture	*C M Gosden*	348
Prenatal chromosome analysis and its impact on the birth incidence of chromosome disorders	*M A Ferguson-Smith*	355
The reduction of neural tube defects by maternal serum alpha-fetoprotein screening	*M A Ferguson-Smith*	365
Amniotic fluid tests for fetal neural tube defects	*D J H Brock*	373
Inherited metabolic disorders	*A D Patrick*	378
Prevention of the haemoglobinopathies	*B Modell*	386
Fetal haemophilia and allied bleeding disorders	*R S Mibashan & D S Millar*	392
Prenatal diagnosis of fetal immunological disorders	*D C Linch & R J Levinsky*	399

Notes on Contributors 405